Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wayne Gulliver

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Journal of Cutaneous Medicine and Surgery|September 15, 2017
An Open Letter to Health CanadaKim Papp, Lorne Albrecht, Kirk Barber, et al.
Cancers|August 12, 2023
Assessing Skin Cancer Risk Factors, Sun Safety Behaviors and Melanoma Concern in Atlantic Canada: A Comprehensive Survey StudyFrançois Lagacé, Bibi Nuzha Noorah, Santina Conte, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 14, 2026
Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and IIThrasyvoulos Tzellos, Evangelos J Giamarellos-Bourboulis, Kelsey R van Straalen, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|February 24, 2015
Insights and advances in chronic urticaria: a Canadian perspectiveGordon Sussman, Jacques Hébert, Wayne Gulliver, et al.
Journal of the American Academy of Dermatology|January 25, 2021
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa FoundationsAmit Garg, Neeta Malviya, Andrew Strunk, et al.
BMJ Open|December 23, 2022
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trialRebecca H Haberman, Katrina A MacFarlane, Sydney Catron, et al.
Journal of the American Academy of Dermatology|December 26, 2024
North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populationsRaed Alhusayen, Serena Dienes, Megan Lam, et al.
Dermatology (Basel, Switzerland)|January 11, 2023
External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa CohortKelsey R van Straalen, Thrasyvoulos Tzellos, Afsaneh Alavi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 5, 2026
Building the foundations for an international patient-centred outcomes set for psoriasis: A scoping studyEmma Vyvey, Rani Soenen, Hazel H Oon, et al.
Genome Medicine|December 17, 2025
Genetic liability to psoriasis predicts severe disease outcomesJake R Saklatvala, Samuel Lessard, Maris Teder-Laving, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Journal of Cutaneous Medicine and Surgery|September 15, 2017
An Open Letter to Health CanadaKim Papp, Lorne Albrecht, Kirk Barber, et al.
Cancers|August 12, 2023
Assessing Skin Cancer Risk Factors, Sun Safety Behaviors and Melanoma Concern in Atlantic Canada: A Comprehensive Survey StudyFrançois Lagacé, Bibi Nuzha Noorah, Santina Conte, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 14, 2026
Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and IIThrasyvoulos Tzellos, Evangelos J Giamarellos-Bourboulis, Kelsey R van Straalen, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|February 24, 2015
Insights and advances in chronic urticaria: a Canadian perspectiveGordon Sussman, Jacques Hébert, Wayne Gulliver, et al.
Journal of the American Academy of Dermatology|January 25, 2021
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa FoundationsAmit Garg, Neeta Malviya, Andrew Strunk, et al.
BMJ Open|December 23, 2022
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trialRebecca H Haberman, Katrina A MacFarlane, Sydney Catron, et al.
Journal of the American Academy of Dermatology|December 26, 2024
North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populationsRaed Alhusayen, Serena Dienes, Megan Lam, et al.
Dermatology (Basel, Switzerland)|January 11, 2023
External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa CohortKelsey R van Straalen, Thrasyvoulos Tzellos, Afsaneh Alavi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 5, 2026
Building the foundations for an international patient-centred outcomes set for psoriasis: A scoping studyEmma Vyvey, Rani Soenen, Hazel H Oon, et al.
Genome Medicine|December 17, 2025
Genetic liability to psoriasis predicts severe disease outcomesJake R Saklatvala, Samuel Lessard, Maris Teder-Laving, et al.
Pageof 9